About this trial

Ofloxacin is a gold standard antibiotic for the treatment of bone and joint infections due to sensible staphylococcus strains. However, in the elderly, inter-individual variability of the pharmacokinetics may reduce the efficacy or increase toxicity. The occurrence of ofloxacin side effects is likely to be increased in case of higher exposition. However, the serum concentration-toxicity relationship has not yet been determined. The purpose of this project is to assess the association between the residual serum concentration of ofloxacin at day 3 and the occurrence of at least one adverse effect attributable to ofloxacin, and determine a threshold toxicity concentration if this association exists.

Eligibility criteria

Qualifiers

Patients aged over 65 years hospitalized at the University Hospital of Amiens for an uncomplicated bone and joint infections

Indication for oral switch to ofloxacin

Disqualifiers

Patient refusing to participate in the study

Patient under guardianship or curators or deprived of public rights

Any liver or biliary injury

Any contraindications to ofloxacin

Trial design

Treatments tested in this trial

  • ofloxacin
  • questionnaire
  • Ofloxacin Serum concentration

Treatment groups

No treatment groups listed

Locations

1
CHU Amiens80480, Amiens France

Sponsors and collaborators

Centre Hospitalier Universitaire, Amiens

Lead sponsor